Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action that normalizes VEGF expression.
End of study, 40-week results demonstrated that MGB, delivered via subcutaneous (subQ) administration, is safe and well-tolerated with no MGB treatment-related ocular or systemic serious adverse events.
This Phase 2 clinical study showed improvements in efficacy outcomes and a marked reduction in the need for supplemental intravitreal anti-VEGF injections in both study and fellow eyes of DME and nAMD participants.
MGB has the potential for safe at-home administration, exhibiting a bilateral treatment effect with a single monthly subQ administration that may be an alternative option to frequent in-office intravitreal injections.
REDWOOD CITY, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood-retinal barrier in areas of inflammation selectively targeting activated cells in the retina, today announced positive topline end-of-study results from its Phase 2 study of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) at the 25th European Society of Retina Specialists (EURETINA) Congress.
